MedPath

Novavax Stock Surges After FDA Approves Updated COVID-19 Vaccine

• Novavax stock rose by 19.2% to $14.68 following FDA authorization of its updated COVID-19 vaccine targeting the JN.1 strain for individuals aged 12 and older. • The updated vaccine is the only non-mRNA option available in the U.S. for this age group, and Novavax anticipates meeting revenue guidance for the 2024/2025 vaccine season. • Novavax is transitioning to an R&D-focused model, currently conducting a Phase 3 trial for a combination flu and COVID-19 vaccine, potentially leading to a major partnership in 2025. • Financial analysts at Jefferies maintain a 'Buy' rating on Novavax stock with a price target of $31, reflecting optimism about the company's prospects and strategic shift.

Novavax (NVAX) experienced a significant surge in its stock price after the U.S. Food and Drug Administration (FDA) granted emergency use authorization for its updated protein-based COVID-19 vaccine. Shares of the biotechnology company rose 19.2% to close at $14.68 following the announcement. The updated vaccine targets the JN.1 strain of the virus and is approved for individuals aged 12 years and older, offering a crucial alternative in the evolving landscape of COVID-19 vaccination.

FDA Authorization and Vaccine Details

The FDA's authorization makes Novavax's product the only non-mRNA vaccine option available in the United States for individuals aged 12 and older. This provides an alternative for those who may prefer or require a non-mRNA vaccine. The vaccine is formulated to target the JN.1 strain, addressing a prevalent variant of the virus.

Financial Outlook and Revenue Guidance

Novavax anticipates meeting its revenue guidance for the 2024/2025 vaccine season, with the majority of sales expected in the fourth quarter. This outlook suggests stability in the company's financial performance amidst evolving COVID-19 vaccination efforts. The company's financial health has also been bolstered by a deal with Sanofi, which is expected to provide upfront payments and potential future earnings, supporting Novavax's ongoing strategic transformation.

Strategic Shift to R&D

Novavax is transitioning to a research and development (R&D) focused model. Currently, the company is conducting a Phase 3 trial for a combination flu and COVID-19 vaccine. This project could potentially lead to a major partnership in 2025, opening new avenues for growth and collaboration within the pharmaceutical industry. Novavax is also exploring new non-seasonal vaccines based on its unique adjuvant technology, which could drive significant future growth.

Analyst Optimism

Financial analysts at Jefferies have expressed optimism about Novavax's prospects, maintaining a "Buy" rating on the stock with a price target of $31. This target represents potential upside from the current trading price, reflecting confidence in the company's strategic direction and growth potential.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Novocure Reports Revenue Growth and FDA Approvals in 2024

Novocure, a global oncology company, announced significant revenue growth and operational advancements for 2024, including FDA approvals for its Tumor Treating Fields therapy and new devices. The company reported a 19% increase in annual net revenues and anticipates further growth with new product launches.

Novavax Achieves $50 Million Milestone in Sanofi Partnership Amidst Combination Vaccine Progress

Novavax has secured a $50 million milestone payment from Sanofi, triggered by progress in the Phase 2/3 clinical trial of its COVID-19 vaccine in children.
Sanofi's combination vaccine candidates, which include Novavax's COVID-19 vaccine, have entered Phase 1/2 trials and received FDA Fast Track designation.

Syndax Pharmaceuticals' Revuforj Receives FDA Approval for Acute Leukemia with KMT2A Translocation

Syndax Pharmaceuticals' Revuforj (revumenib) has gained FDA approval for treating acute leukemia in adult and pediatric patients with KMT2A translocation.
The approval was based on Phase 1/2 AUGMENT-101 trial data, demonstrating a 21% complete response rate and a median response duration of 6.4 months.

FDA Lifts Clinical Hold on Novavax's Phase 3 COVID-19/Flu Vaccine Study

The FDA has lifted the clinical hold on Novavax's Phase 3 trial for its COVID-19/influenza combination and stand-alone influenza vaccine candidates.
The hold was initiated due to a serious adverse event reported in a Phase 2 trial participant, which was later determined to be unrelated to the vaccine.

NovoCure's Optune Receives FDA Approval for Expanded Use in Non-Small Cell Lung Cancer

NovoCure's Optune has received FDA approval for use in non-small cell lung cancer (NSCLC) after platinum-based treatments fail.
The approval allows Optune to be used with PD-1/PD-L1 inhibitors or docetaxel, significantly broadening its market potential.

Novavax's Updated COVID-19 Vaccine Now Available at Major U.S. Pharmacies

Novavax's 2024-2025 formula COVID-19 vaccine (NVX-CoV2705) is now stocked at major pharmacies across the U.S. for individuals aged 12 and older.
The updated vaccine targets the JN.1 variant and has demonstrated cross-reactivity against JN.1 lineage viruses, offering a protein-based alternative.

FDA Approves Digital Therapeutic for GAD, Updated Novavax COVID-19 Vaccine, and New Insulin Patch Pump

The FDA cleared DaylightRX, the first digital therapeutic for generalized anxiety disorder (GAD), to be used as an adjunct to usual care for patients aged 22 years and older.
Novavax received emergency use authorization (EUA) from the FDA for its updated COVID-19 vaccine, NVX-CoV2705, for individuals aged 12 years and older.

Novavax COVID-19 Vaccine Targeting JN.1 Authorized for Emergency Use in the U.S.

The FDA has granted Emergency Use Authorization (EUA) for Novavax's updated COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.
The updated vaccine targets the JN.1 variant and demonstrates cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3 and LB.1.

Novavax COVID-19 Vaccine Receives FDA Emergency Use Authorization for 2023-2024 Formula

The FDA has granted Emergency Use Authorization (EUA) for Novavax's COVID-19 vaccine (NVX-CoV2601) for individuals aged 12 and older.
The updated vaccine targets current variants, including XBB.1.5, XBB.1.16, and XBB.2.3, offering a protein-based, non-mRNA option.

FDA Grants Accelerated Approval to Dabrafenib and Trametinib Combination for BRAF V600E-Mutated Solid Tumors

The FDA granted accelerated approval to Novartis' dabrafenib and trametinib combination for BRAF V600E-mutated solid tumors.
This approval targets adult and pediatric patients (≥6 years) with unresectable or metastatic tumors who progressed after prior treatment.

Reference News

[1]
Novavax (NVAX) Stock Rises 19% After FDA Approval for Updated COVID-19 Vaccine
moneycheck.com · Oct 3, 2024

Novavax stock surged 19.2% to $14.68 after FDA authorized its updated COVID-19 vaccine for ages 12+ targeting JN.1 strai...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy